| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Vivimed Labs Limited (NSE: VIVIMEDLAB)
VIVIMEDLAB Technical Analysis
1
| As on N/A VIVIMEDLAB SHARE Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS. |
VIVIMEDLABSHARE Price
| Open | N/A | Change | Price | % |
| High | N/A | 1 Day | N/A | N/A |
| Low | N/A | 1 Week | N/A | N/A |
| Close | N/A | 1 Month | N/A | N/A |
| Volume | N/A | 1 Year | N/A | N/A |
| 52 Week High N/A | 52 Week Low N/A | ||||
NSE INDIA Most Active Stocks
| IDEA | 6.69 | -3.32% |
| YESBANK | 18.23 | -0.22% |
| CANBK | 95.37 | 1.81% |
| WELSPUNLIV | 137.89 | 2.16% |
| PNB | 91.36 | -3.07% |
| SUZLON | 53.15 | -2.83% |
| GTLINFRA | 1.36 | -2.16% |
| IDFCFIRSTB | 66.42 | -0.81% |
| MOTHERSON | 141.47 | -0.69% |
| EASEMYTRIP | 12.12 | -0.66% |
NSE INDIA Top Gainers Stocks
| GINNIFILA | 28.64 | 19.98% |
| PAVNAIND | 371.85 | 18.99% |
| SHANKARA | 689.05 | 17.62% |
| GRINDWELL | 1771.30 | 14.67% |
| SHRIPISTON | 2121.50 | 14.00% |
| KRISHANA | 338.15 | 12.32% |
| MBAPL | 284.70 | 11.84% |
| NAHARINDUS | 110.43 | 10.54% |
| MHLXMIRU | 234.53 | 10.00% |
| BANG | 50.79 | 9.96% |
NSE INDIA Top Losers Stocks
| VIVIMEDLAB Daily Charts |
VIVIMEDLAB Intraday Charts |
Whats New @ Bazaartrend |
VIVIMEDLAB Free Analysis |
|
|
VIVIMEDLAB Important Levels Intraday
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE |
VIVIMEDLAB Target May 2025
| 4th UP Target | |
| 3rd UP Target | |
| 2nd UP Target | |
| 1st UP Target | |
| 1st DOWN Target | |
| 2nd DOWN Target | |
| 3rd DOWN Target | |
| 4th DOWN Target |
VIVIMEDLAB Weekly Target
| 4th UP Target | |
| 3rd UP Target | |
| 2nd UP Target | |
| 1st UP Target | |
| 1st DOWN Target | |
| 2nd DOWN Target | |
| 3rd DOWN Target | |
| 4th DOWN Target |
VIVIMEDLAB Target2025
| 4th UP Target | |
| 3rd UP Target | |
| 2nd UP Target | |
| 1st UP Target | |
| 1st DOWN Target | |
| 2nd DOWN Target | |
| 3rd DOWN Target | |
| 4th DOWN Target |
Vivimed Labs Limited ( NSE INDIA Symbol : VIVIMEDLAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VIVIMEDLAB Synopsis Technicals View
| 50 Day EMA |
Close is Below EMA 50 (Short Term) |
Bearish | |
| 100 Day EMA | Close is Below EMA 100 (Mid Term) | Bearish | |
| 200 Day EMA | Close is Below EMA 200 (Long Term) | Bearish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is 40.99 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Short Sell | 10.24 | |
| 10 Day Avg Volume | Traded 171.64 % More then 10 Day Average Volume | ||
VIVIMEDLAB Other Details
| Segment | EQ | |
| Market Capital | 1504887296.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
VIVIMEDLAB Address
 |
||
VIVIMEDLAB Latest News
VIVIMEDLAB Business Profile
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India. Address: North End, Hyderabad, India, 500034
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service